JP MORGAN/CALL/EDWARDS LIFESCIENCES/130/0.1/15.11.24

JP MORGAN/CALL/EDWARDS LIFESCIENCES/130/0.1/15.11.24 Stock

DE000JK58HZ5

Real-time Bid/Ask 06:54:02 2024-06-03 am EDT
0.027 ^EUR / 0.11 ^EUR	+213.64%

1 month

-8.33%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart EDWARDS LIFESCIENCES CORPORATION

Chart JP MORGAN/CALL/EDWARDS LIFESCIENCES/130/0.1/15.11.24

Latest news about EDWARDS LIFESCIENCES CORPORATION

Becton, Dickinson to Acquire Edwards Lifesciences' Critical Care Product Group for $4.2 Billion	06:48am	MT
BD to Acquire Edwards Lifesciences' Critical Care Product Group for $4.2 Billion to Expand Smart Connected Care Solutions and Become an Advanced Monitoring Technology Leader	06:31am	PR
Edwards Lifesciences to Sell Critical Care to BD	06:31am	BU
Some of the biggest splits in Corporate America	May. 23	RE

More news

Quotes 5-day view

Date	Price	Change
24-06-03	0.018	-18.18%
24-05-31	0.022	+15.79%
24-05-30	0.019	+18.75%
24-05-29	0.016	-30.43%
24-05-28	0.023	+4.55%

Delayed Quote Börse Stuttgart

Last update June 03, 2024 at 05:20 am EDT

More quotes

Static data

Product type	Warrants
Buy / Sell	CALL
Underlying	EDWARDS LIFESCIENCES CORPORATION
Issuer	J.P. Morgan
WKN	JK58HZ
ISIN	DE000JK58HZ5
Date issued	2024-04-11
Strike	130 $
Maturity	2024-11-15 (166 Days)
Parity	10 : 1
Emission price	0.12 €
Emission volume	N/A
Settlement	Por diferencias
Currency	EUR

Technical Indicators

Highest since issue	0.093 €
Lowest since issue	0.015 €
Delta	0x
Omega	0.000000
Premium	0x
Gearing	186.45x
Moneyness	1.072
Difference Strike	43.11 $
Difference Strike %	+33.16%
Spread	0.102 €
Spread %	85.00%
Intrinsic value	0.8662
Present value	-0.797688

Company Profile

Edwards Lifesciences Corporation specializes in designing, manufacturing and marketing medical systems and devices for treating cardiovascular diseases. Net sales break down by family of products as follows: - heart valves and surgery products (67.9%); - hemodynamic monitoring systems (15.5%); - other (16.6%): balloon catheters, artificial implants, etc. Net sales are distributed geographically as follows: the United States (58.4%), Europe (22.2%), Japan (7.6%) and other (11.8%).

Sector

More about the company

Ratings for Edwards Lifesciences Corporation

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Consensus: Edwards Lifesciences Corporation

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

86.89 USD

Average target price

96.55 USD

Spread / Average Target

+11.12%

Consensus